Literature DB >> 17087931

Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization.

Mi-Young Kim1, Seon-Hee Yim, Mi-Seon Kwon, Tae-Min Kim, Seung-Hun Shin, Hyun-Mi Kang, Charles Lee, Yeun-Jun Chung.   

Abstract

BACKGROUND & AIMS: Although genetic aspects of tumorigenesis in colorectal cancer (CRC) have been well studied, reliable biomarkers predicting prognosis are scarce. We aimed to identify recurrently altered genomic regions (RAR) in CRC with high resolution, to investigate their implications on survival and to explore novel cancer-related genes in prognosis-associated RARs.
METHODS: A 1-Mb resolution microarray-based comparative genomic hybridization (array CGH) was applied to 59 CRCs. RARs, defined as genomic alterations, detected in more than 10 cases were identified and analyzed for their association with survival. Expression levels of genes in prognosis-associated RARs were examined by real-time quantitative polymerase chain reaction.
RESULTS: Twenty-seven RARs were identified. Eleven high-level amplifications and 2 homozygous deletions also were detected, but they were not as common as RARs. Multivariate analysis revealed RAR-L1 (loss on 1p36; hazard ratio = 8.15, P = .002) and RAR-L20 (loss on 21q22; hazard ratio = 3.53, P = .034) are independent indicators of poor prognosis. Expression of CAMTA1, located in RAR-L1, was reduced frequently in CRCs, and low CAMTA1 expression was associated significantly with poor prognosis, which indicates that CAMTA1 may play a role as a tumor suppressor in CRC. Five pairs of RARs were correlated significantly to each other and 3 pairs share genes involved in the same biological functions, suggesting possible collaborative roles in tumorigenesis.
CONCLUSIONS: We identified recurrent genomic changes in 59 CRCs. RARs could be more important in sporadic tumors where the effect of genomic changes on tumorigenesis is relatively smaller than in familial cancer. Our results and analysis strategy will be helpful to elucidate pathogenesis of CRCs or to develop biomarkers for predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087931     DOI: 10.1053/j.gastro.2006.10.021

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Altered expression of the PMAIP1 gene: A major player in the evolution of gastrointestinal and systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Dig Dis Sci       Date:  2008-03-05       Impact factor: 3.199

2.  Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array.

Authors:  Seung-Hyun Jung; Seung-Hun Shin; Seon-Hee Yim; Hye-Sun Choi; Sug-Hyung Lee; Yeun-Jun Chung
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

3.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

4.  Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.

Authors:  Jih-Hsiang Lee; Elisa Giovannetti; Jin-Hyeok Hwang; Iacopo Petrini; Qiuyan Wang; Johannes Voortman; Yonghong Wang; Seth M Steinberg; Niccola Funel; Paul S Meltzer; Yisong Wang; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-11-29       Impact factor: 12.531

5.  Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome.

Authors:  Jordi Camps; Marian Grade; Quang Tri Nguyen; Patrick Hörmann; Sandra Becker; Amanda B Hummon; Virginia Rodriguez; Settara Chandrasekharappa; Yidong Chen; Michael J Difilippantonio; Heinz Becker; B Michael Ghadimi; Thomas Ried
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

6.  CDX2 is an amplified lineage-survival oncogene in colorectal cancer.

Authors:  Keyan Salari; Mary E Spulak; Justin Cuff; Andrew D Forster; Craig P Giacomini; Stephanie Huang; Melissa E Ko; Albert Y Lin; Matt van de Rijn; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

7.  Genome-wide analysis of survival in early-stage non-small-cell lung cancer.

Authors:  Yen-Tsung Huang; Rebecca S Heist; Lucian R Chirieac; Xihong Lin; Vidar Skaug; Shanbeh Zienolddiny; Aage Haugen; Michael C Wu; Zhaoxi Wang; Li Su; Kofi Asomaning; David C Christiani
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

8.  Clinical applications of next-generation sequencing in colorectal cancers.

Authors:  Tae-Min Kim; Sug-Hyung Lee; Yeun-Jun Chung
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

9.  Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.

Authors:  R P M Brosens; E J T H Belt; J C Haan; T E Buffart; B Carvalho; H Grabsch; P Quirke; M A Cuesta; A F Engel; B Ylstra; G A Meijer
Journal:  Cell Oncol (Dordr)       Date:  2011-06-30       Impact factor: 6.730

10.  Lumican and versican are associated with good outcome in stage II and III colon cancer.

Authors:  Meike de Wit; Eric J Th Belt; Pien M Delis-van Diemen; Beatriz Carvalho; Veerle M H Coupé; Hein B A C Stockmann; Herman Bril; Jeroen A M Beliën; Remond J A Fijneman; Gerrit A Meijer
Journal:  Ann Surg Oncol       Date:  2012-06-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.